ZORO study: Discrepancy between the conclusion and the results

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3340-

  Blumenfeld, Zeev ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

ACCURACY; CANCER CHEMOTHERAPY; CONVALESCENCE; FEMALE; FEMALE FERTILITY; HUMAN; LETTER; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION; OVARIAN PRESERVATION; OVARY FUNCTION; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GOSERELIN; HUMANS; OVARY;

EID: 80051989947     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.9850     Document Type: Letter

References (3)

1. Gerber B., Von Minckwitz G., Stehle H., et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
2. Del Mastro L., Boni L., Michelotti A., et al: Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 28:7s, 2010 (suppl; abstr 528)
3. Badawy A., Elnashar A., El-Ashry M., et al: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril 91:694-697, 2009